[HTML][HTML] Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
…, S Negoro, T Sugiura, A Yokoyama… - … England Journal of …, 2002 - Mass Medical Soc
Background Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell
lung cancer. In a phase 2 study of irinotecan plus cisplatin in patients with extensive small…
lung cancer. In a phase 2 study of irinotecan plus cisplatin in patients with extensive small…
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis
…, M Ando, T Sawa, K Muro, H Ueoka, A Yokoyama… - Cancer research, 2000 - AACR
Irinotecan unexpectedly causes severe toxicity of leukopenia or diarrhea. Irinotecan is
metabolized to form active SN-38, which is further conjugated and detoxified by UDP-…
metabolized to form active SN-38, which is further conjugated and detoxified by UDP-…
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the …
…, M Kawahara, T Sugiura, A Yokoyama… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: To evaluate the optimal timing for thoracic radiotherapy (TRT) in limited-stage
small-cell lung cancer (LS-SCLC), the Lung Cancer Study Group of the Japan Clinical …
small-cell lung cancer (LS-SCLC), the Lung Cancer Study Group of the Japan Clinical …
Age-related remodelling of oesophageal epithelia by mutated cancer drivers
A Yokoyama, N Kakiuchi, T Yoshizato, Y Nannya… - Nature, 2019 - nature.com
Clonal expansion in aged normal tissues has been implicated in the development of cancer.
However, the chronology and risk dependence of the expansion are poorly understood. …
However, the chronology and risk dependence of the expansion are poorly understood. …
[HTML][HTML] The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption
…, MA Enoch, D Goldman, TK Li, A Yokoyama - PLoS …, 2009 - journals.plos.org
… Akira Yokoyama … Akira Yokoyama … Ishikawa H, Ishikawa T, Yamamoto H, Fukao A,
Yokoyama K (2007) Genotoxic effects of alcohol in human peripheral lymphocytes …
Yokoyama K (2007) Genotoxic effects of alcohol in human peripheral lymphocytes …
Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics.
A Yokoyama, T Muramatsu, T Ohmori… - …, 1998 - academic.oup.com
Aldehyde dehydrogenase-2 (ALDH2) eliminates most of the acetaldehyde produced during
alcohol metabolism. In some drinkers, a mutant ALDH2 allele contributes to diminished …
alcohol metabolism. In some drinkers, a mutant ALDH2 allele contributes to diminished …
Alcohol and aldehyde dehydrogenase gene polymorphisms and oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics
A Yokoyama, T Muramatsu, T Omori… - …, 2001 - academic.oup.com
Alcohol dehydrogenase-2 (ADH2) and aldehyde dehydrogenase-2 (ALDH2) gene polymorphisms
play roles in ethanol metabolism, drinking behavior and esophageal carcinogenesis …
play roles in ethanol metabolism, drinking behavior and esophageal carcinogenesis …
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the …
S Atagi, M Kawahara, A Yokoyama, H Okamoto… - The lancet …, 2012 - thelancet.com
Background It is unknown whether combined chemoradiotherapy improves overall survival
in elderly patients with locally advanced non-small-cell lung cancer (NSCLC). The aim of this …
in elderly patients with locally advanced non-small-cell lung cancer (NSCLC). The aim of this …
Genetic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S -transferase M1 and drinking, smoking, and diet in Japanese men …
A Yokoyama, H Kato, T Yokoyama, T Tsujinaka… - …, 2002 - academic.oup.com
The genetic polymorphisms of aldehyde dehydrogenase-2 (ALDH2), alcohol dehydrogenase-2
(ADH2), ADH3, and glutathione S -transferase M1 (GSTM1) influence the metabolism of …
(ADH2), ADH3, and glutathione S -transferase M1 (GSTM1) influence the metabolism of …
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301
…, H Isobe, H Okamoto, T Ogura, A Yokoyama… - Journal of Clinical …, 2006 - ascopubs.org
Purpose This multicenter, phase II study was conducted to evaluate the activity of amrubicin,
a topoisomerase II inhibitor, against refractory or relapsed small-cell lung cancer (SCLC). …
a topoisomerase II inhibitor, against refractory or relapsed small-cell lung cancer (SCLC). …